Experimental study on antitumor effect of arsenic trioxide in combination with cisplatin or doxorubicin on hepatocellular carcinoma

Table 1 CDI value of As₂O₃ in combination with PDD against Bel-7402 cells

Cell line	As2O3 (mg•L¯¹)	PDD (mg•L¯¹)
		0.25	0.5	1	2
Bel-7	1	0.60	0.60	1.00	1.22
	2	0.62	0.70	1.03	1.38
	4	0.60	0.65	1.13	1.50

Table 2 CDI value of As₂O₃ in combination with ADM against Bel-7402 cells

Cell line	As2O3 (mg•L¯¹)	ADM (mg•L¯¹)
		0.3125	0.625	1.25	2.5
Bel-7	1	1.03	1.02	1.05	1.12
	2	1.03	0.98	1.06	1.31
	4	1.00	1.05	1.08	1.28

Table 3 The effect of As₂O₃ and/or PDD on HepA implanted tumor in mice (n = 10)

Groups	Dose (mg•kg¯¹•d¯¹)	Tumor mass (¯x ± s, g)	Inhibition (%)	Q value
Control	NS	1.53 ± 0.35
As2O3	2	1.07 ± 0.21	30.1
PDD	1	0.82 ± 0.11	46.2
As2O3+PDD	2+1	0.40 ± 0.05	73.9a	1.18

^aP ＜ 0.01, F = 54.05, vs As₂O₃ or PDD alone.

Table 4 The effect of As₂O₃ and/or ADM on HepA implanted tumor in mice (n = 10)

Groups	Dose (mg•kg¯¹•d¯¹)	Tumor mass (¯x ± s, g)	Inhibition (%)	Q value
Control	NS	1.53 ± 0.35
As2O3	2	1.07 ± 0.21
ADM	1	0.91 ± 0.12	40.5
As2O3+ADM	2+1	0.61 ± 0.11	60.1a	1.03

^aP ＜ 0.05, F = 24.40, vs As₂O₃ or ADM alone.